Tislelizumab
Based on 3 publication(s) in Google Scholar
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma.
For research use only. We do not sell to patients.
- Purity: 98.10%
- CAS No.: 1858168-59-8
- Molecular Weight:145 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Tislelizumab
More-
ELISA
Biological Activity
Human IgG4 kappa
Human
PDCD1/PD-1/CD279
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:B16F10/GM-CSF tumor cells treated hPD-1 C57BL/6 transgenic mice[2]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection (i.p.); once a week for 4 weeks.
-
Result:Exerted remarkable antitumor efficacy, resulting in approximate 86.7% tumor growth inhibition.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1858168-59-8
-
Appearance Liquid
-
Molecular Weight 145 kDa
-
Color Colorless to light yellow
-
SMILES
[Tislelizumab]
-
Synonyms
BGB-A317
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
N-deglycosylation targeting chimera (DGlyTAC): a strategy for immune checkpoint proteins inactivation by specifically removing N-glycan. [Abstract]2025 Apr 28;10(1):139. PMID: 40289109 -
J Pharm Anal
Increasing the tumour targeting of antitumour drugs through anlotinib-mediated modulation of the extracellular matrix and the RhoA/ROCK signalling pathway. [Abstract]2024 Aug;14(8):100984. PMID: 39258171 -
Cancer Cell Int
Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer. [Abstract]2024 Jun 29;24(1):225. PMID: 38951894
Tislelizumab purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2024 Jun 29;24(1):225. [Abstract]
Tislelizumab (50 µg/mL; 24 h). IFN-γ concentration in the supernatant of co-cultured cell lines was assessed by ELISA.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Jie Wang, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5):709-717. [Content Brief]
[2]. Hong Y, et al. Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage. FEBS Open Bio. 2021 Mar;11(3):782-792. [Content Brief]
[3]. Zhu K, et al. Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients. Front Pharmacol. 2024 Feb 22;15:1355081. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)